Taipei, August 3, 2026
GlycoNex Inc. announced that the first patient has been successfully dosed in the first-in-human Phase I clinical trial of GNX1021, the company’s novel glycan-targeting antibody-drug conjugate (ADC), in Japan. The milestone moves GlycoNex’s lead oncology candidate from preclinical research into clinical development and begins the generation of the first human data for GNX1021. The transition represents an important development milestone for the Taiwan-based clinical-stage biopharmaceutical company as it evaluates a differentiated approach to targeting tumors through cancer-associated glycan structures rather than relying solely on conventional protein receptor targets.
GNX1021 Enters First-in-Human Phase I Clinical Development
The multinational, multicenter Phase I study is being conducted in Japan and Taiwan and will evaluate GNX1021 across multiple dose levels in patients with advanced solid tumors. The clinical trial is designed to assess several important measures, including safety and tolerability, pharmacokinetics, immunogenicity, preliminary anti-tumor activity and the recommended dose for subsequent clinical development. Data generated from the study are expected to guide future dose selection and help establish the broader development strategy for GNX1021. GlycoNex said the findings could also support potential evaluation of the investigational therapy in selected gastrointestinal cancer populations. By moving into human testing, GNX1021 begins the process of generating clinical safety, pharmacokinetic and early activity evidence that will determine the future direction of the program. GlycoNex also views the milestone as an opportunity to increase the maturity of its lead oncology asset and strengthen the program’s positioning for potential strategic collaborations.
Glycan-Directed ADC Targets Gastrointestinal Malignancies
GNX1021 is directed against the branched Lewis B/Y, or bLeB/Y, glycan antigen, which according to GlycoNex is highly expressed in gastric cancer and other gastrointestinal malignancies, while demonstrating limited expression in normal tissue. The candidate is differentiated from many ADCs by its approach to tumor recognition. While most ADC programs currently in development target a specific protein receptor, GNX1021 is designed to recognize a tumor-associated glycan structure displayed across multiple carrier molecules on the cancer-cell surface. GlycoNex believes this mechanism could potentially broaden the range of addressable tumor targets, enhance tumor selectivity and help address challenges associated with tumor heterogeneity. The clinical trial will now provide the first opportunity to evaluate the candidate’s profile directly in patients. As an investigational therapy in an early-stage study, GNX1021’s safety and therapeutic activity will need to be established through clinical development. The program is the lead candidate generated from the company’s proprietary GlycoSH anti-glycan antibody library, which is also being used to develop additional glycan-directed ADCs and related therapeutic candidates.
Advertisement
GlycoNex Builds Glycan-Targeted Oncology and ADC Pipeline
The initiation of Phase I dosing represents a broader milestone for GlycoNex’s glycan-directed oncology strategy. The company has more than two decades of experience in glycobiology and antibody development and has established an integrated organization spanning drug discovery, cell-line and process development, analytics, clinical manufacturing and clinical development. In addition to GNX1021, GlycoNex is developing a pipeline of glycan-targeted antibody-drug conjugates and maintains biosimilar programs supported by international development and manufacturing partnerships. With GNX1021 now in clinical development, the company plans to explore potential regional and global licensing, co-development and other strategic collaboration opportunities while continuing to evaluate the program’s long-term clinical and commercial strategy. The first-patient-dosed milestone is particularly significant because it shifts GNX1021 from preclinical evidence toward the generation of human data needed to characterize its safety, pharmacokinetics and preliminary anti-tumor activity. Results from the Phase I study will therefore be important in determining whether glycan-directed targeting can provide a differentiated therapeutic strategy within the rapidly expanding ADC field. For GlycoNex, advancing GNX1021 into its first-in-human Phase I trial establishes a clinical foundation for both its lead asset and its broader glycan-targeted oncology platform.
Source: GlycoNex press release
